Posted inDiabetes & Endocrinology Gastroenterology news
Head-to-Head Comparison of Empagliflozin and Dapagliflozin on Liver Outcomes in Type 2 Diabetes with MASLD
A large Korean cohort study found similar hepatic benefits between empagliflozin and dapagliflozin in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease, with no difference in risk of severe liver complications.